Health Canada Grants Marketing Authorization for KALYDECO (i

Health Canada Grants Marketing Authorization for KALYDECO (ivacaftor) for Patients With Cystic Fibrosis Between the Ages of 4 Months and 18 Years With the R117H Mutation in the CFTR Gene - read this article along with other careers information, tips and advice on BioSpace

Related Keywords

Canada , Boston , Massachusetts , United States , Australia , Cambridge , Cambridgeshire , United Kingdom , Toronto , Ontario , London , City Of , America , Michael Siauw , Exchange Commission , Vertex Pharmaceuticals Canada Inc , Vertex Pharmaceuticals Canada , Vertex Pharmaceuticals Canada Incorporated , Health Canada , Marketing Authorization , General Manager , Vertex Pharmaceuticals , Innovation District , North America , Top Employers , Private Securities Litigation Reform Act , Resume , Careers , Ealth Canada Grants Marketing Authorization For Kalydeco Ivacaftor Patients With Cystic Fibrosis Between The Ages Of 4 Months And 18 Years R117h Mutation In Cftr Gene , Iospace , Advice ,